Hair relaxer cancer lawsuit: chemical straightener litigation guide

Understanding the hair relaxer cancer litigation

The hair relaxer cancer litigation represents one of the most significant emerging mass torts in the United States, alleging that manufacturers of chemical hair straightening and relaxer products failed to warn consumers about an elevated risk of uterine cancer, ovarian cancer, and other hormone-sensitive malignancies. These lawsuits have brought national attention to the intersection of consumer product safety, environmental health, and racial justice, as the products at issue are predominantly marketed to and used by Black women.

At the heart of this litigation is a landmark 2022 study from the National Institutes of Health (NIH) and the National Institute of Environmental Health Sciences (NIEHS), which found that women who frequently used chemical hair straightening products had more than double the risk of developing uterine cancer compared to women who did not use these products. This study, published in the Journal of the National Cancer Institute, provided the scientific foundation for thousands of lawsuits.

For personal injury attorneys, the hair relaxer litigation offers a unique combination of strong scientific evidence, deep-pocket defendants, a large and identifiable plaintiff population, and compelling social justice narratives that resonate with juries.

The NIH Sister Study found that women who frequently used chemical hair straighteners had more than 150% higher uterine cancer rates — approximately 4.05% of frequent users vs. 1.64% of non-users would develop uterine cancer by age 70.

The science: NIH/NIEHS Sister Study and cancer risk

The scientific evidence linking chemical hair relaxers to cancer centers primarily on the Sister Study, a prospective cohort study conducted by the NIEHS that enrolled 50,884 women aged 35 to 74 between 2003 and 2009. Participants were followed for an average of 10.9 years, during which researchers tracked cancer diagnoses and analyzed the association between hair product use and cancer outcomes.

Uterine cancer findings

The most striking finding was the association between chemical hair straightener use and uterine cancer. Women who reported using chemical hair straightening products more than four times in the previous year had a rate of uterine cancer that was more than 150% higher than non-users. Even less frequent users showed elevated risk.

Ovarian cancer association

Additional research using data from the large prospective Black Women's Health Study found that long-term use of chemical hair relaxers was associated with an increased risk of ovarian cancer, with the association being strongest among women who used these products for extended periods.

Breast cancer research

The Sister Study also identified a modest association between chemical hair product use and breast cancer. A 2019 analysis found that women who used chemical hair straighteners at least every five to eight weeks had approximately a 30% higher risk of breast cancer. The association was notably stronger among Black women.

Endocrine-disrupting chemicals in hair relaxer products

The biological mechanism linking hair relaxer use to cancer involves endocrine-disrupting chemicals (EDCs) that interfere with the body's hormonal systems, mimicking, blocking, or altering the activity of natural hormones.

Scalp absorption: a unique exposure pathway

The scalp has a high density of hair follicles, each providing a direct pathway to the dermis and underlying blood vessels. Chemical relaxers are left on the scalp for extended periods (15 to 30+ minutes), and their highly alkaline formulations (pH 10 to 14) can cause burns and lesions that further compromise the skin barrier and increase absorption. Studies have documented elevated biomarker levels of phthalates, parabens, and other EDCs in the blood and urine of hair relaxer users, confirming systemic absorption.

Defendant manufacturers and product identification

The hair relaxer litigation involves claims against multiple major manufacturers. Identifying the specific products used by each plaintiff is essential for establishing defendant liability.

MDL 3060: Northern District of Illinois

In February 2023, the JPML created MDL No. 3060, In Re: Hair Relaxer Marketing Sales Practices and Products Liability Litigation, consolidating federally filed hair relaxer cases in the Northern District of Illinois before Judge Mary M. Rowland. The MDL has entered active discovery, with defendants producing internal documents related to product formulation, testing, marketing, and knowledge of EDC content and cancer risk.

Discovery and bellwether process

Bellwether case selection is underway, with both sides proposing representative cases for early trial. The bellwether process will test key issues including general causation, specific causation, and damages. Defendants are expected to challenge admissibility of expert testimony through Daubert motions.

The disproportionate impact on Black women

The hair relaxer litigation carries a profound social justice dimension because the products at issue are predominantly used by Black women. Cultural, social, and economic pressures related to Eurocentric beauty standards have driven widespread use of chemical hair straightening products in the Black community for decades. An estimated 85% or more of Black women have used chemical hair relaxers at some point in their lives, and many begin using these products in childhood or adolescence.

This disproportionate use pattern means that Black women bear a disproportionate burden of hair relaxer-related cancer risk. Uterine cancer rates among Black women have been increasing faster than among women of other races, and Black women with uterine cancer face worse outcomes and higher mortality rates. Plaintiffs' attorneys have argued that the manufacturers' failure to warn constitutes a form of environmental injustice.

Qualifying criteria for hair relaxer cancer claims

Effective case qualification is critical for building a successful hair relaxer caseload. The following criteria reflect the standard screening factors used by most plaintiff firms and litigation funding partners.

Cancer diagnosis requirements

The strongest cases involve plaintiffs diagnosed with uterine cancer (endometrial cancer), ovarian cancer, or uterine sarcoma. Some firms are also evaluating cases involving breast cancer, endometriosis, and uterine fibroids. A pathologically confirmed cancer diagnosis documented in medical records is essential.

Product use history

Plaintiffs must demonstrate a history of regular use of chemical hair straightening or relaxer products. Most qualification criteria require at least four years of product use, with frequency of at least two to four applications per year. Longer duration and more frequent use strengthen the case.

Temporal relationship

The cancer diagnosis should have occurred during or after a period of hair relaxer use, with a biologically plausible latency period. The latency period for hormone-sensitive cancers typically ranges from several years to decades.

Settlement projections and case valuations

Talcum powder litigation, which involved similar allegations linking a consumer product to ovarian cancer, produced individual trial verdicts ranging from millions to billions of dollars and eventual settlement funds totaling over $8 billion from Johnson & Johnson alone. While direct comparisons should be made cautiously, the talcum powder litigation demonstrates the potential scale of recoveries in consumer product cancer cases.

Legal theories in hair relaxer cancer cases

• Failure to warn: Manufacturers knew or should have known about cancer risks from EDCs and failed to provide adequate warnings to consumers. Because these are consumer products, the duty to warn runs directly to the end user.
• Design defect: The inclusion of EDCs made products unreasonably dangerous. Consumers would not expect a cosmetic product to contain carcinogenic chemicals, and alternative formulations were available.
• Negligence: Manufacturers failed to exercise reasonable care in formulating, testing, and marketing products — including failure to monitor emerging scientific literature on EDC risks.
• Fraudulent concealment: Manufacturers actively concealed known risks and made affirmative misrepresentations about product safety, including marketing claims of "natural," "organic," or "gentle" formulations.
• Punitive damages: Evidence of targeting a vulnerable population while concealing known risks supports punitive damages that may significantly exceed compensatory damages.

Building a strong hair relaxer cancer case

Building a compelling case requires careful attention to both the scientific evidence of general causation and the specific evidence linking each plaintiff's cancer to her product use.

Product use documentation

Because hair relaxer products are purchased over the counter and used over periods of years or decades, documenting product use history can be challenging. Attorneys should conduct thorough client interviews to reconstruct use history, including approximate age of first use, frequency, specific products and brands, and method of application. Corroborating evidence may include testimony from family members and hairdressers, purchase records, salon records, and photographs.

Expert testimony requirements

Hair relaxer cases require expert testimony on general causation (whether EDCs in hair relaxers can cause cancer), specific causation (whether the plaintiff's individual cancer was caused by her use), toxicology and endocrine disruption mechanisms, and damages. Experts in epidemiology, toxicology, gynecologic oncology, and endocrinology are typically needed.

Regulatory landscape and FDA actions

The Modernization of Cosmetics Regulation Act (MoCRA), signed into law in December 2022, grants the FDA new authority to require adverse event reporting, mandate recalls, require facility registration, and establish good manufacturing practices for cosmetics. Several states have also enacted legislation restricting specific chemicals in cosmetic products, providing additional evidence that the chemicals at issue are recognized health hazards.

How hair relaxer cases fit into a mass tort portfolio

Hair relaxer cases offer several attractive characteristics for personal injury firms building mass tort portfolios: strong scientific evidence from a prestigious government study, multiple deep-pocket corporate defendants, a large plaintiff population, and compelling narratives. Firms with experience in other consumer product or toxic exposure mass torts, such as Roundup or talcum powder litigation, will find natural synergies with hair relaxer practice.

Working with a specialized hair relaxer lead generation partner can accelerate portfolio building while ensuring that acquired cases meet the qualifying criteria established by MDL leadership and litigation funding partners.